From: Long-term outcome of patients after a single interruption of antiretroviral therapy: a cohort study
Variable | Number of patients (percentage), except where specified |
---|---|
Median age (range) | 37 years (23–63) |
Male gender | 45 (68) |
Risk category | |
Injection drug users | 28(42) |
Men who have sex with men | 16 (24) |
Heterosexual | 22 (34) |
Toxic habits | |
Current smoking | 46 (69) |
Alcholism | 22 (33) |
Methadone Maintenance Treatment | 20 (30) |
Median time since diagnosis of HIV infection (range) | 10 years (2–16) |
CDC category | |
A | 54 (82) |
B | 6 (9) |
C | 6 (9) |
Number of previous antiretroviral regimens | |
1 | 13 (20) |
2 | 16 (24) |
3 or more | 37 (56) |
Median time on HAART before interruption (range) | 284 weeks (60–512) |
Adherence <80% to any previous antiretroviral therapy | 20 (30) |
Previous virologic failure with any antiretroviral regimen | |
No | 53 (81) |
Yes | 13 (19) |
HCV coinfection | 33 (50) |
HBV coinfection | 2 (3) |
Median HIV-1 VL at diagnosis (range) | 23.750 copies/mL (100–1.511.000) |
Median nadir CD4+ cell count (range) | 252 cells/μL (50–552) |
Main reason for the interruption of HAART | |
Proposed by physician | 33 (50) |
Intolerance to current regimen | 20 (30,3) |
Decision of the patient | 10 (15,2) |
Problems for an appropriate adherence | 3 (4,5) |
Median CD4+ cell count at interruption (range) | 745 (350–2132) |